Active Ingredient History
Autologous cultured chondrocytes on porcine collagen membrane (Maci) is a treatment to correct cartilage defects in the knee. It is used to treat symptomatic, full-thickness cartilage defects of the knee with or without bone involvement. Autologous cultured chondrocytes on porcine collagen membrane is an autologous cellularized scaffold product. This treatment is approved by the US Food and Drug Administration (FDA). It is only administered to adults. Healthy cartilage is removed from the person's own knees and a 'scaffold' is created on which the healthy tissue growths. This is an autologous matrix-induced chondrogenesis procedure which prevents tissue rejection complications since the transplanted cartilage comes from the same person. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Cartilage Diseases (approved 1997)
Bone Cysts (Phase 1)
Cartilage (Phase 1)
Cartilage, Articular (Phase 4)
Cartilage Diseases (Phase 3)
Congenital Microtia (Early Phase 1)
Fractures, Bone (Phase 1)
Intervertebral Disc Degeneration (Phase 2)
Intervertebral Disc Displacement (Phase 1/Phase 2)
Joint Diseases (Phase 1/Phase 2)
Liver Cirrhosis (Phase 1)
Mandibular Condyle (Phase 2)
Nasal Septal Perforation (Phase 1)
Osteoarthritis, Hip (Phase 1)
Osteochondritis (Phase 3)
Osteochondritis Dissecans (Phase 3)
Temporomandibular Joint Disorders (Phase 1)
Traumatology (Phase 3)
Vesico-Ureteral Reflux (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
